Phaseline

Companies › Chongqing Precision Biotech

Chongqing Precision Biotech: clinical trials, targets and expected readouts

16 active drug programs in 28 registered trials: 27 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
pCAR-19B cells
CD19-directed autologous CAR-T cell therapy
–Phase 2Acute Lymphoblastic LeukemiaDec 2028
Anti-CD19 UCAR-T cells
anti-CD19 CAR-T cell therapy
CD19Phase 1Dermatomyositis, JuvenileNov 2026
PIC1 Injection
CAR-T cell therapy
–Phase 1Non-Hodgkin LymphomaDec 2026
BCMA targeted prime CAR-T cells
anti-BCMA CAR-T cell therapy
BCMAPhase 1Multiple MyelomaDec 2026
CD19 and CD22 targeted prime CAR-T cells
CAR-T cell therapy targeting CEA (CEACAM5)
CD19, CEACAM5Phase 1B-ALL; Advanced Lung Cancer; Systemic Lupus ErythematosusDec 2026
CD70 CAR-T cells
anti-CD70 CAR-T cell therapy
CD70Phase 1Ovarian Cancer; Metastatic TumorDec 2026
CEA-targeted CAR-T cells
anti-CEA chimeric antigen receptor T cell therapy
CEACAM5Phase 1Gastric Cancer; Colorectal Cancer; Lung Cancer; Peritoneal Metastases From Colorectal Cancer …Dec 2026
MC-1-50
CD19-targeted CAR-T cell therapy
CD19Phase 1B Cell Lymphoma; Systemic Lupus Erythematosus (SLE)Dec 2026
Anti-CD5 CAR NK cells
anti-CD5 CAR-NK cell therapy
CD5Phase 1T-ALL/LymphomaMar 2027
Anti-CD123 CAR NK cells
anti-CD123 CAR-NK cells
CD123Phase 1AML (Acute Myeloid Leukemia)Jun 2027
CD19-targeted CAR-T
CAR-T cell therapy targeting CD19
CD19Phase 1Juvenile DermatomyositisJul 2027
Invivo CAR-T
CAR-T cell therapy
–Phase 1B-Acute Lymphoblastic LeukemiaDec 2027
PTOC1
CD19-targeted CAR-T cell therapy
CD19Phase 1Systemic Lupus ErythematosusApr 2028
PICX Injection
In vivo CAR-T cell therapy
–Phase 1Relapsed or Refractory Multiple Myeloma (RRMM)Apr 2028
BCMA/CD70 CAR-T cells
Dual-targeted CAR-T cell therapy against BCMA and CD70
TNFRSF17, CD70Phase 1Systemic Lupus ErythematosusAug 2028
BCMA/CD70-targeted CAR-T
Dual-targeted CAR-T cell therapy against BCMA and CD70
BCMA, CD70Phase 1Juvenile Dermatomyositis (JDM)Sep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06686524Anti-CD19 UCAR-T cellsPhase 1Dermatomyositis, JuvenileImmunologyNov 2026
NCT07456371PIC1 InjectionPhase 1Non-Hodgkin LymphomaOncologyDec 2026
NCT06126406CEA-targeted CAR-T cellsPhase 1Gastric CancerOncologyDec 2026
NCT06043466CEA-targeted CAR-T cellsPhase 1Colorectal CancerOncologyDec 2026
NCT06180174MC-1-50Phase 1B Cell LymphomaOncologyDec 2026
NCT04781634CD19 and CD22 targeted prime CAR-T cellsPhase 1B-ALLOncologyDec 2026
NCT06768151CD19 and CD22 targeted prime CAR-T cellsPhase 1Advanced Lung CancerOncologyDec 2026
NCT04776330BCMA targeted prime CAR-T cellsPhase 1Multiple MyelomaOncologyDec 2026
NCT04271644BCMA targeted prime CAR-T cellsPhase 1Multiple MyelomaOncologyDec 2026
NCT06215950CD70 CAR-T cellsPhase 1Ovarian CancerOncologyDec 2026
NCT06909474Anti-CD5 CAR NK cellsPhase 1T-ALL/LymphomaOncologyMar 2027
NCT05518253CD70 CAR-T cellsPhase 1Metastatic TumorOncologyMay 2027
NCT07247396CEA-targeted CAR-T cellsPhase 1Peritoneal Metastases From Colorectal CancerOncologyMay 2027
NCT06690827Anti-CD123 CAR NK cellsPhase 1AML (Acute Myeloid Leukemia)OncologyJun 2027
NCT06569472CD19-targeted CAR-TPhase 1Juvenile DermatomyositisImmunologyJul 2027
NCT07239323Invivo CAR-TPhase 1B-Acute Lymphoblastic LeukemiaOncologyDec 2027
NCT06945523CD19 and CD22 targeted prime CAR-T cellsPhase 1Advanced Lung CancerOncologyDec 2027
NCT06903117CD19 and CD22 targeted prime CAR-T cellsPhase 1Advanced Lung CancerOncologyDec 2027
NCT06892145MC-1-50Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyFeb 2028
NCT06992583CD19 and CD22 targeted prime CAR-T cellsPhase 1Advanced Lung CancerOncologyFeb 2028
NCT07179692CEA-targeted CAR-T cellsPhase 1Lung CancerOncologyMar 2028
NCT07403097PTOC1Phase 1Systemic Lupus ErythematosusImmunologyApr 2028
NCT07715630PICX InjectionPhase 1Relapsed or Refractory Multiple Myeloma (RRMM)OncologyApr 2028
NCT07250386CEA-targeted CAR-T cellsPhase 1NSCLC (Advanced Non-small Cell Lung Cancer)OncologyJun 2028
NCT07318259BCMA/CD70 CAR-T cellsPhase 1Systemic Lupus ErythematosusImmunologyAug 2028
NCT07331467CD19 and CD22 targeted prime CAR-T cellsPhase 1Systemic Lupus ErythematosusImmunologyAug 2028
NCT07184450BCMA/CD70-targeted CAR-TPhase 1Juvenile Dermatomyositis (JDM)ImmunologySep 2028
NCT05334823pCAR-19B cellsPhase 2Acute Lymphoblastic LeukemiaOncologyDec 2028

Targets

CD19 (5) CD70 (3) CEACAM5 (2) BCMA (2) CD123 (1) TNFRSF17 (1) CD5 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Allogene Therapeutics iCell Gene Therapeutics Beijing Biotech Johnson & Johnson (Janssen) AstraZeneca Roche Gracell Biotechnologies (Shanghai) Miltenyi Biomedicine

Companies built like this

iCell Gene Therapeutics Jiangsu Topcel-KH Pharmaceutical Hrain Biotechnology PersonGen BioTherapeutics (Suzhou) Hebei Senlang Biotechnology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.